Abstract
Background-Depression is a common comorbidity in heart failure and is strongly associated with increased mortality, morbidity, and reduced health status. Whether depression treatment may result in improvement of health status in heart failure patients with comorbid depression remains unknown. Methods and Results-The Sertraline Against Depression and Heart Disease in Chronic Heart Failure study randomized 469 participants with chronic heart failure (left ventricular ejection fraction 45% and New York Heart Association class II) and major depressive disorder based on Diagnostic Statistics Manual fourth edition criteria to sertraline or placebo for 12 weeks. The Kansas City Cardiomyopathy Questionnaire, 36-Item Short-Form Health Survey, and 6-minute walk test were used to assess health status. Health status changes between treatment arms and remission status were evaluated adjusting for baseline variables and treatment assignment. The final Hamilton Depression Rating Scale scores were 3.50±2.08 and 12.97±4.33 in the remission and nonremission groups, respectively (P value=0.0001). Of 469 total participants, 378 (80.6%) completed the 6-minute walk test and 285 (70.1%) completed Kansas city cardiomyopathy questionnaire and 36-item short-form health survey, at baseline and at week 12. Depression remission was significantly associated with higher improvements in Kansas City Cardiomyopathy Questionnaire subscale scores (P<0.001) except on the Self-Efficacy (P=0.18) and Symptom Stability (P=0.91). On the 36-Item Short-Form Health Survey, depression remission was associated with significant improvement in subscales of the physical and mental component summary except the Pain Index (P=0.34). The 6-minute walk test improved more in depression remission compared with nonremission group (difference from baseline: 63.51±238.78 versus 16.24±115.70 m, P=0.03). Conclusions-Patients with heart failure whose depressive symptoms remitted had significantly greater improvement in physical function, social function, and quality of life.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 688-692 |
| Number of pages | 5 |
| Journal | Circulation: Heart Failure |
| Volume | 5 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2012 |
Fingerprint
Keywords
- 6-Minute walk test
- Depression
- Health status
- Heart failure
- Kansas City Cardiomyopathy Questionnaire
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Health status and depression remission in patients with chronic heart failure. / Xiong, Glen; Fiuzat, Mona; Kuchibhatla, Maragatha; Krishnan, Ranga; O'Connor, Christopher M.; Jiang, Wei.
In: Circulation: Heart Failure, Vol. 5, No. 6, 11.2012, p. 688-692.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Health status and depression remission in patients with chronic heart failure
AU - Xiong, Glen
AU - Fiuzat, Mona
AU - Kuchibhatla, Maragatha
AU - Krishnan, Ranga
AU - O'Connor, Christopher M.
AU - Jiang, Wei
PY - 2012/11
Y1 - 2012/11
N2 - Background-Depression is a common comorbidity in heart failure and is strongly associated with increased mortality, morbidity, and reduced health status. Whether depression treatment may result in improvement of health status in heart failure patients with comorbid depression remains unknown. Methods and Results-The Sertraline Against Depression and Heart Disease in Chronic Heart Failure study randomized 469 participants with chronic heart failure (left ventricular ejection fraction 45% and New York Heart Association class II) and major depressive disorder based on Diagnostic Statistics Manual fourth edition criteria to sertraline or placebo for 12 weeks. The Kansas City Cardiomyopathy Questionnaire, 36-Item Short-Form Health Survey, and 6-minute walk test were used to assess health status. Health status changes between treatment arms and remission status were evaluated adjusting for baseline variables and treatment assignment. The final Hamilton Depression Rating Scale scores were 3.50±2.08 and 12.97±4.33 in the remission and nonremission groups, respectively (P value=0.0001). Of 469 total participants, 378 (80.6%) completed the 6-minute walk test and 285 (70.1%) completed Kansas city cardiomyopathy questionnaire and 36-item short-form health survey, at baseline and at week 12. Depression remission was significantly associated with higher improvements in Kansas City Cardiomyopathy Questionnaire subscale scores (P<0.001) except on the Self-Efficacy (P=0.18) and Symptom Stability (P=0.91). On the 36-Item Short-Form Health Survey, depression remission was associated with significant improvement in subscales of the physical and mental component summary except the Pain Index (P=0.34). The 6-minute walk test improved more in depression remission compared with nonremission group (difference from baseline: 63.51±238.78 versus 16.24±115.70 m, P=0.03). Conclusions-Patients with heart failure whose depressive symptoms remitted had significantly greater improvement in physical function, social function, and quality of life.
AB - Background-Depression is a common comorbidity in heart failure and is strongly associated with increased mortality, morbidity, and reduced health status. Whether depression treatment may result in improvement of health status in heart failure patients with comorbid depression remains unknown. Methods and Results-The Sertraline Against Depression and Heart Disease in Chronic Heart Failure study randomized 469 participants with chronic heart failure (left ventricular ejection fraction 45% and New York Heart Association class II) and major depressive disorder based on Diagnostic Statistics Manual fourth edition criteria to sertraline or placebo for 12 weeks. The Kansas City Cardiomyopathy Questionnaire, 36-Item Short-Form Health Survey, and 6-minute walk test were used to assess health status. Health status changes between treatment arms and remission status were evaluated adjusting for baseline variables and treatment assignment. The final Hamilton Depression Rating Scale scores were 3.50±2.08 and 12.97±4.33 in the remission and nonremission groups, respectively (P value=0.0001). Of 469 total participants, 378 (80.6%) completed the 6-minute walk test and 285 (70.1%) completed Kansas city cardiomyopathy questionnaire and 36-item short-form health survey, at baseline and at week 12. Depression remission was significantly associated with higher improvements in Kansas City Cardiomyopathy Questionnaire subscale scores (P<0.001) except on the Self-Efficacy (P=0.18) and Symptom Stability (P=0.91). On the 36-Item Short-Form Health Survey, depression remission was associated with significant improvement in subscales of the physical and mental component summary except the Pain Index (P=0.34). The 6-minute walk test improved more in depression remission compared with nonremission group (difference from baseline: 63.51±238.78 versus 16.24±115.70 m, P=0.03). Conclusions-Patients with heart failure whose depressive symptoms remitted had significantly greater improvement in physical function, social function, and quality of life.
KW - 6-Minute walk test
KW - Depression
KW - Health status
KW - Heart failure
KW - Kansas City Cardiomyopathy Questionnaire
UR - http://www.scopus.com/inward/record.url?scp=84873688807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873688807&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.112.967620
DO - 10.1161/CIRCHEARTFAILURE.112.967620
M3 - Article
VL - 5
SP - 688
EP - 692
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
SN - 1941-3297
IS - 6
ER -